AI symptom tracker aims to catch early colon cancer in young adults

NCT ID NCT07618273

Recruiting now Symptom relief Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a smartphone app called Smart Symptom Tracking ALEX can help young adults (ages 18-44) track gastrointestinal symptoms better than traditional paper logs. The app uses artificial intelligence to provide reminders, coaching, and education. Researchers want to see if the app improves how well people report symptoms and communicate with their doctors, which could lead to earlier detection of colorectal cancer. The trial involves 50 participants over four weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Smart Symptom Tracking ALEX app (AI-based digital platform)
What this could lead to: If it works, this could give young adults a better way to track GI symptoms and communicate concerns to doctors, potentially leading to earlier detection of colorectal cancer.
What could go wrong: This is a small, early feasibility study with only 50 participants. The app may not improve symptom tracking or health outcomes compared to standard paper logs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal carcinoma colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Florida
RECRUITING

Jacksonville, Florida, 32224-9980, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.